Aankondiging • Apr 16

Tvardi Therapeutics, Inc. completed the acquisition of Cara Therapeutics, Inc. (NasdaqCM:CARA) from Vifor (International) AG and others in a reverse merger transaction.

Tvardi Therapeutics, Inc. executed a term sheet to acquire Cara Therapeutics, Inc. (NasdaqCM:CARA) from Vifor (International) AG and others in a reverse merger transaction on November 3, 2024. Tvardi Therapeutics, Inc. entered into an agreement to acquire Cara Therapeutics, Inc. (NasdaqCM:CARA) from Vifor (International) AG and others in a reverse merger transaction on December 17, 2024. At the effective time of the reverse stock split, every three (3) issued and outstanding shares of Cara Therapeutics, Inc’s common stock will automatically be combined into one (1) issued and outstanding share of Cara Therapeutics, Inc’s common stock without any change in the par value per share. The reverse stock split will reduce the number of issued and outstanding shares of Cara Therapeutics, Inc’s common stock from approximately 4.6 million to approximately 1.5 million. Upon completion of the Merger, the combined company is expected to operate under the name Tvardi Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “TVRD”. As of April 14, 2025 Cara’s common stock is expected to begin trading on a reverse stock split-adjusted basis at the opening of the market on Wednesday, April 16, 2025 under the new name “Tvardi Therapeutics, Inc.” and under the new symbol “TVRD” following the anticipated closing of the merger (the “Merger”) with Tvard Therapeutics, Inc. (“Tvardi”), with a new CUSIP number 140755 307. Following the Closing, Imran Alibhai, Ph.D., the Chief Executive Officer of Tvardi, will serve as the President and Chief Executive Officer of the combined company, Dan Conn, J.D., M.B.A, the Chief Financial Officer of Tvardi, will serve as the Chief Financial Officer of the combined company, John Kauh, M.D., the Chief Medical Officer of Tvardi, will serve as the Chief Medical Officer of the combined company, Jeffrey Larson, Ph.D., DABT, the Senior Vice President, Research & Development of Tvardi, will serve as the Senior Vice President, Research & Development of the combined company and Yixin “Joseph” Chen, Ph.D., the Vice President, Chemistry, Manufacturing and Controls of Tvardi, will serve as the Vice President, Chemistry, Manufacturing and Controls of the combined company. Additionally, following the Closing, the board of directors of the combined company will consist of seven directors and will be comprised of six members designated by Tvardi (including Sujal Shah, the current Chairman of the Tvardi board of directors, Imran Alibhai, Ph.D., Wallace Hall, Shaheen Wirk, M.D. and Michael Wyzga each of whom are current members of the Tvardi board of directors), one vacancy and one member to be designated by Cara prior to Closing. In connection with the Closing, Christopher Posner, Ryan Maynard and Scott Terrillion are expected to cease to be the officers of the Company and the existing Cara directors not remaining with the combined company are expected to tender their resignations from the board of directors of the company. The merger agreement contains certain termination rights of each of Tvardi and Cara. Upon termination of the merger agreement in certain circumstances, a termination fee of $2.25 million may be payable by a party. The transaction has been approved by both parties both of directors. As of April 1, 2025 shareholders of Cara Therapeutics, Inc. approved the transaction. The closing is subject to certain mutual closing conditions, including: (i) no order preventing the merger and the other transactions and actions contemplated by the merger agreement having been issued and remaining in effect and there being no law which has the effect of making the consummation of merger and the other transactions and actions contemplated by the merger Agreement illegal; (ii) the required approvals by the parties’ stockholders having been obtained; (iii) the existing shares of Cara Common Stock having been continually listed on Nasdaq and the shares of Cara Common Stock to be issued in the merger being approved for listing on Nasdaq; (iv) the Form S-4 having become effective in accordance with the Securities Act of 1933, as amended and (v) a determination pursuant to the merger agreement that Cara Net Cash will be at least $18.0 million as of the Closing. The transaction is expected to close in the first half of 2025. As of April 14, 2025, the transaction is expected that it will become effective as of 4:01 p.m. Eastern Time on Tuesday, April 15, 2025. Daniel Bagliebter and Kenneth Koch of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo acted as legal advisor to Cara Therapeutics. Div Gupta; Rama Padmanabhan; Carlos Ramirez; Matthew D. Silverman; Anitha Anne; Patricia Myers; Michael Bergmann; Ross Eberly; Lila Hope; Xander Lee; Phil Mitchell; Howard Morse; Francis Wheeler; Natasha Leskovsek; Andrew Epstein; Reid Hooper; Justin Kisner; Dani Nazemian; Stella Sarma; Karen Tsai; Julia R. Brinton and Rachel F. Katz of Cooley LLP and Goodwin Procter LLP acted as legal advisors to Tvardi Therapeutics. Piper Sandler & Co. acted as fairness opinion provider to Cara Therapeutics. Piper Sandler & Co. acted as financial advisor to Cara Therapeutics. In connection with Piper Sandler’s services as the financial advisor to the Cara Board, Cara agreed to pay Piper Sandler a fee of $2,500,000, which is contingent upon consummation of the Merger (the Success Fee) and a fee of $500,000 (the Opinion Fee), which was earned by Piper Sandler upon delivery of the Piper Sandler Opinion. Alliance Advisors LLC acted as proxy solicitor to Cara Therapeutics and is required to pay a fee of $50,000 plus certain additional cost. Syneos Health, Inc. acted as due diligence provider to Cara. Equiniti Trust Company, LLC acted as transfer agent to Cara Therapeutics. Tvardi Therapeutics, Inc. completed the acquisition of Cara Therapeutics, Inc. (NasdaqCM:CARA) from Vifor (International) AG and others in a reverse merger transaction in April 15, 2025. The combined company is operating under the name Tvardi Therapeutics, Inc., and its shares will trade on the Nasdaq Capital Market under the ticker symbol TVRD. The combined company will be led by Imran Alibhai, Ph.D., its Chief Executive Officer, and other members of the Tvardi management team.

Seeking Alpha • Sep 01

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Summary Korsuva has been approved in an indication for which, it faces little in the way of competition. A number of expansion opportunities await oral difelikefalin, with positive phase 2 data for NP opening the door to additional indications. Language surrounding launch metrics and sales for Q3 sounds cautious, and a near-term disappointment could weigh on share price. Steady history of insider sales and lack of specialist biotech funds holding positions here are possible negative indicators. CARA is a Buy, but only suitable for long-term investors. Key risks include disappointing data for ongoing studies (especially placebo effect) and competition in certain indications (atopic dermatitis). Shares of Cara Therapeutics (CARA) are down 20% over the past 5 years. So far in 2022, they are 15% in the red. I'm always on the lookout for commercial-stage ideas, especially new product launches as that potent combination of accelerating sales momentum and pipeline progress can be hard to resist. Cara caught my eye given the Korsuva launch is underway for an indication (CKD-aP in HD) in which it is the first and only product approved, in addition to bullish remarks from management in the Q2 report where they state "we anticipate demand to accelerate in the coming months, driven by large dialysis organizations that started purchasing early in the third quarter." From what I understand, the positive KOMFORT phase 2 readout in notalgia paresthetica could serve as POC and open the door to multiple other disease categories in both the neurological and dermatology space. Let's take a closer look to determine if Cara fits our criteria for the Core Biotech portfolio and whether there's sufficient commercial and clinical momentum to merit gaining exposure here. Chart FinViz Figure 1: CARA weekly chart When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the weekly chart above, we can see a share price spike to the $30 level in Q2 2021 when the FDA and EMA accepted regulatory applications for difelikefalin injection (Korsuva) for the treatment of pruritus associated with chronic kidney disease in hemodialysis patients. From there, the market certainly "taketh away" as the stock plunged on a setback in a mid-stage study in atopic dermatitis. In summer 2022, the share price bottomed around in the $8 level and has slightly rebounded to $10. Overall, I think we are looking at a depressed chart and valuation, so long term investors who believe better days are coming would do well to accumulate a position in the current range. Overview Founded in 2004 with headquarters in Connecticut (84 employees), Cara Therapeutics currently sports an enterprise value of ~$350M and Q2 cash position of $204M providing them operational runway for roughly 2 years (I imagine they will access funds via financing by mid 2023 or so). Management's presentation at Canaccord Genuity Growth Conference provides an excellent overview: CEO Christopher Posner and CMO Joana Goncalvez are present, with Posner noting that the company is focused on pruritus (itching) and has an approved therapy Korsuva injection (approved last August). They launched in April this year with partner Vifor Pharma (recently acquired by CSL) with favorable economics in terms of launch. They also have a pipeline-in-a-drug approach with oral difelikefalin and two phase 3 programs initiated this quarter or Q1 (atopic dermatitis and chronic kidney disease in patients pre-dialysis). Third priority is around expanding utilization of oral difelikefalin via two phase 2 programs (recent positive topline data for notalgia paresthetica or NP, and a small phase 2 POC study in primary biliary cholangitis with data readout 2H 22). They have a very strong balance sheet, $204M and guidance to 1H 24 (does not include revenue received from launch). Corporate Slides Figure 2: Combined patient opportunity across lead indications Q2 was the first quarter of launch, total net sales were $17M of which Cara's profit share was $8M. That was comprised mainly of channel stocking (launch inventory in anticipation of future demand). Initial demand is driven by smaller dialysis organizations and recently they got formulary coverage of two largest dialysis organizations (comprise 80% of the market). Recently they announced that the Fresenius Medical Care salesforce is joining the promotional mix as well. They expect demand to steadily increase over the next couple quarters and Q3 will draw down some of that inventory they put in the channel (sounds conservative). Total addressable patient population is 200,000 and most of those preside with Fresenius and DaVita for whom they have formulary coverage. They are fully reimbursed by Medicare for minimum of 2 years (granted in April) via TDAPA designation (only other analogue is Amgen's parsabiv launched in 2018 and they had TDAPA designation for 3 years). Once they get out of the TDAPA payment, the product goes into the bundle and they would expect it to increase to cover an innovative drug like Korsuva. One distinction though is that parsabiv went into the bundle with two other drugs including generic oral version that shifted incentive to generic, whereas Korsuva would go into the bundle with additional funding without any additional competition as there are no competitors in that functional category). CMS recently came out with proposed rule for 2023 for end stage renal disease patients in the bundle/payment system, and they specifically call out concerns for drugs designated with TDAPA (proposed four options that all are positive in terms of adding additional money outside the bundle for an innovative drug like Korsuva). We probably won't hear back from them on this issue until 2024. Early days of launched, shipped 1800 vials to dialysis clinics and anecdotally feedback is quite positive (very high levels of awareness among nephrologists and very high intent to treat). Week over week they are seeing increases in number of clinics ordering and majority of them reordering (gives hope that they are having positive first experiences with the product). Moving on to oral Korsuva, NP indication is an interesting opportunity and affects 650,000 patients. It's treated by medical dermatologists and there are no FDA-approved therapies for this neuropathic itch. The strategy is to look at their drug in systemic, dermatologic and neuropathic conditions to demonstrate broad utility. Data showed that the drug works broadly across disease areas regardless of the underlying pathogenesis (what's causing that itch). It also confirmed the mechanism of action, works with strong neuro-modulatory manner to inhibit the itch. Corporate Slides Figure 3: Positive POC data in NP shows path forward to broader utility NP is a more homogenous type of itch and patient (itch is just neuropathic and strong data is a result of strong neuro-modulatory effect). Atopic dermatitis itch is a combination of inflammatory component as well as neuro-modulatory, so oral difelikefalin should work there. The company's phase 3 program is using it as an adjunct to topical corticosteroids (address inflammatory itch) while difelikefalin addresses the neuro-modulatory. In systemic itch, pathogenesis is multi-factorial and drug should work there given prior data. Placebo response does vary by condition. NP is the first study (nothing else is in trials) and going forward data has been submitted to dermatological conference (placebo response could go higher in the future). 4 point response was the primary endpoint and was around 20%. In Atopic dermatitis they saw 20% placebo effect in mild-to-moderate patient population as well. Stage 3 patients (higher placebo response) have not been included in the ongoing phase 3 study. On the con side, pain and itch are very subjective endpoints. Corporate Slides Figure 4: Phase 2 data in AD focusing on mild-to-moderate subgroup For atopic dermatitis, management acknowledges the evolving competitive landscape and flurry of development in the moderate to severe space and it's all focused on inflammatory component coupled with disease modification. Topicals are still utilized in mild to moderate cases and they are not always effective. Placebo effect to my eyes is the big risk for phase 3 study especially considering the prior phase 2 trial failed to meet the primary endpoint in the moderate to severe population and the company chose to instead focus on the key secondary endpoint (percentage of patients who achieved an improvement from a baseline of ≥4 points in the weekly mean of the daily 24-hour Itch NRS score at week 12, which is now the registration endpoint). They are confident about design being optimal, but reading between the lines I think the CEO sounded less confident on actually achieving the primary endpoint. Majority of these patients they are enrolling are mild to moderate. Safety profile repeatedly shows consistency and predictability. Across different disease areas they see predominantly GI effects, headache and dizziness. With long term use they do not expect it to look any different (events did not increase over time, some decrease over time as they typically occur in first few weeks on treatment). As for phase 2 in PBC, this is a small proof of concept study (just want to see numerical separation and positive signal). They want to see consistent pattern of effect, early onset of action and sustained effect. For the IV product, they are fully-partnered with Vifor in the US and EU (who owns nearly 14% of the company, not a stretch to think they decide to simply buy Cara out at some point). For wholly-owned oral difelikefalin, they will look for ex US partnerships and in the US retain the option to 'go it solo' in commercializing (especially for concentrated markets). Other Information For the second quarter of 2022, the company reported cash and equivalents of $204M as compared to $30M cash used in operating activities. Net loss was $4.2M, while total revenues amounted to $23M ($15M milestone payment for Kapruvia approval and $8M in collaboration revenue related to profit-sharing). Research and development expenses fell to $19.9M, while G&A rose to $7.6M. Again, management is guiding for operational runway into 1H 2024 (this is conservative, as they are not including any product revenue received or milestone payments that could come). Accumulated deficit is $480M and again I would expect another financing at some point in 2023, perhaps the back half of the year. On the conference call, regarding launch metrics and what to expect in the future, management reminds us that for them to record revenue Vifor must ship to wholesalers and then demand is generated (sounds again like Q3 could be soft or below expectations before the ensuing uptick). The CEO expects demand to accelerate into the back half of the year as Fresenius and Davita are online, formulary protocols are in place and they are starting to see ordering done by clinics. Again, keep in mind that the $8M in revenue received on net sales of just under $17M amounts to 47% of net sales (assumes 60% profit split at non-Fresenius accounts). As for prior financings, the July 2019 secondary offering took place at price point of $23/share (representing a double from current levels). Moving on to nuggets from other presentations, the KOMFORT readout call was certainly worth listening to: The big idea here with oral difelikefalin (DFK) is to provide clinical benefit regardless of underlying cause of pruritus, to treat it across a broad variety of disease categories. NP data affirms core strategy is on target and on track. As for market opportunity in NP, they estimate 2.7M adults have neuropathic itch including NP (disease significantly underdiagnosed with only a quarter of NP patients under care of a provider). There are no FDA approved therapies and off label treatments currently used have little or no efficacy or safety & tolerability concerns. In addition to data mentioned in Figure 3, significantly greater proportion of patients on DFK achieved 4 point improvement in WI-NRS compared to placebo (endpoint regulators will be looking at in pivotal studies). 41% of patients on DFK versus 18% on placebo with statistical separation versus placebo seen as early as week 2 and sustained through week 8. Corporate presentation Figure 5: Promising efficacy in NP on registrational endpoint As for safety data, there were similar proportion of patients reporting 1 treatment related adverse event on DFK and placebo. Most events were mild to moderate in severity, with one severe event occurring on placebo. 12 patients on DFK (19.4%) and 4 on placebo (6.3%) discontinued due to adverse event (concerningly high number on DFK arm). Dizziness and nausea were most common events. In Q&A, as for rates of discontinuation, management states that discontinuation rate in NP was consistent with what they saw in atopic dermatitis. They will need to do some "dose finding" going forward, but are not considering titration. As for institutional investors of note, I mentioned prior that Vifor owns nearly 14% of the company. Otherwise, a possible red flag or at least neutral point is that I see mainly generalist funds in this one (BlackRock with 13.5% stake and Vanguard with 5.6% stake). As for insiders, CEO Chris Posner owns over 200,00 shares. Steady history of sales by multiple members of leadership over the past year(s) is not encouraging.

Pharmaceuticals Groei van de industrie	5.95%
Inkomstengroei	-26.01%
Rendement op eigen vermogen	n/a
Nettomarge	-992.95%
Laatste winstupdate	31 Dec 2024

Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Dec 24	7	-71	27	0
30 Sep 24	9	-96	27	-47
30 Jun 24	11	-111	27	0
31 Mar 24	17	-123	29	0
31 Dec 23	21	-119	29	0
30 Sep 23	21	-117	30	79
30 Jun 23	27	-112	29	0
31 Mar 23	43	-84	29	0
31 Dec 22	42	-85	31	0
30 Sep 22	39	-89	36	0
30 Jun 22	49	-66	35	0
31 Mar 22	26	-93	34	0
31 Dec 21	23	-88	31	0
30 Sep 21	134	24	25	-6
30 Jun 21	123	8	25	0
31 Mar 21	129	14	24	0
31 Dec 20	135	8	23	0
30 Sep 20	28	-99	20	6
30 Jun 20	24	-115	19	0
31 Mar 20	24	-113	18	0
31 Dec 19	20	-106	18	0
30 Sep 19	21	-98	18	0
30 Jun 19	20	-85	17	0
31 Mar 19	18	-79	16	0
31 Dec 18	13	-74	15	0
30 Sep 18	8	-68	14	0
30 Jun 18	3	-61	14	0
31 Mar 18	0	-53	13	0
31 Dec 17	1	-58	12	0
30 Sep 17	1	-66	11	0
30 Jun 17	1	-65	9	0
31 Mar 17	1	-69	9	0
31 Dec 16	0	-57	9	0
30 Sep 16	0	-45	9	0
30 Jun 16	3	-38	9	0
31 Mar 16	3	-31	8	0
31 Dec 15	4	-25	8	0
30 Sep 15	5	-19	7	0
30 Jun 15	3	-21	7	0
31 Mar 15	3	-19	7	0
31 Dec 14	3	-18	6	0
30 Sep 14	3	-16	5	1
30 Jun 14	3	-14	5	2

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/04/16 10:56
Aandelenkoers aan het einde van de dag	2025/04/15 00:00
Inkomsten	2024/12/31
Jaarlijkse inkomsten	2024/12/31

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

Analist	Instelling
Jason Matthew Gerberry	BofA Global Research
Kenneth Trbovich	Brean Capital Historical (Janney Montgomery)
Corey Davis	Canaccord Genuity

This company is no longer active

Cara Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2024 earnings released: US$15.53 loss per share (vs US$26.26 loss in FY 2023)

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cara Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

Tvardi Therapeutics, Inc. completed the acquisition of Cara Therapeutics, Inc. (NasdaqCM:CARA) from Vifor (International) AG and others in a reverse merger transaction.

Full year 2024 earnings released: US$15.53 loss per share (vs US$26.26 loss in FY 2023)

Cara Therapeutics Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

New major risk - Revenue and earnings growth

Tvardi Therapeutics, Inc. entered into an agreement to acquire Cara Therapeutics, Inc. (NasdaqCM:CARA) from Vifor (International) AG and others in a reverse merger transaction.

New major risk - Share price stability

Cara Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 70% to US$1.52

Nasdaq Grants Cara Therapeutics Additional 180 Days to Regain Compliance with Minimum Closing Bid Price Requirement

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Cara Therapeutics, Inc. Announces Outcome from Dose-Finding Part A of the Kourage-1 Study

We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cara Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Cara Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

Price target decreased by 12% to US$4.90

Full year 2023 earnings: EPS and revenues miss analyst expectations

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Cara Therapeutics, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Cara Therapeutics, Inc. Receives A Non-Compliance Notice from the Nasdaq Stock Market

Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program

Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis

The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

Consensus revenue estimates decrease by 39%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

New major risk - Share price stability

Consensus revenue estimates increase by 19%

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Cara Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target decreased by 7.6% to US$17.29

New minor risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cara Therapeutics, Inc. Appoints Helen M. Boudreau as Member of Board and Audit Committee

New minor risk - Share price stability

Cara Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announces England’s National Institute for Health and Care Excellence has Recommended Kapruvia

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 53%

News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Price target decreased by 18% to US$19.38

Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients

Key Executive recently sold US$111k worth of stock

Cara Therapeutics hires new finance chief

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Calls A Much Safer Way To Buy Cara Therapeutics

We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Consensus revenue estimates increase by 19%

Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Taking A (Speculative) Position In Cara Therapeutics

Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth